Peter Sand to Administration, Cutaneous
This is a "connection" page, showing publications Peter Sand has written about Administration, Cutaneous.
Connection Strength
0.508
-
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb; 206(2):168.e1-6.
Score: 0.102
-
The evolution of transdermal therapy for overactive bladder. Curr Urol Rep. 2009 Sep; 10(5):338-41.
Score: 0.089
-
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
Score: 0.085
-
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
Score: 0.074
-
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006 Dec; 195(6):1730-5.
Score: 0.073
-
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015 Jan; 34(1):37-43.
Score: 0.030
-
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig. 2011; 31(8):559-571.
Score: 0.024
-
Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology. 2006 Apr; 67(4):657-64.
Score: 0.018
-
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug; 62(2):237-42.
Score: 0.015